Eclipse 2000 To Compete Against PLC's Heart Laser In TMR Market
This article was originally published in The Gray Sheet
Executive Summary
PLC Medical's Heart Laser 1% perioperative mortality in stable angina patients may be viewed by cardiac surgeons as a significant advantage over the 5% rate for the Eclipse 2000, which was recommended for approval by FDA's Circulatory System Devices Panel at its Oct. 27 meeting. Both lasers are used in transmyocardial revascularization procedures to treat angina.
You may also be interested in...
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.